Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 21, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the share repurchase transaction:
- Shares Purchased: 1,385,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,160.48 pence per share.
- Treasury Holdings: Following the purchase, the Company holds 496,179,158 shares in Treasury.
- Treasury Percentage: 8.97% of total voting rights.
- Shares in Issue: 5,529,116,383 (excluding Treasury shares).
Material Changes
The material change reported is the increase in Treasury shares from the prior period due to the open market purchase of 1,385,000 shares on November 21, 2007. This transaction reduces the number of shares in issue available to the public and increases the proportion of voting rights held in Treasury.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of shares in issue (5,529,116,383) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (496,179,158) and its impact on the total voting rights structure (8.97% held in Treasury).
- Note that this filing is a notification of a specific share buyback event and does not contain financial performance results.